Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quantification of I2BS in Alzheimer's Disease using [11C]BU99008 PET
NCT02874820Phase 1Terminated
- Sponsor
- Imperial College London
- Start
- Jul 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [11C]BU99008 in Alzheimer's disease (AD), sponsored by Imperial College London. Primary endpoint: Density and distribution of Imidazoline 2 binding sites at 1 year. Started Jul 2016; status: terminated.
02
Drugs
[11C]BU99008
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02874820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874820.